Inclusion Criteria:

- Patients must have histologically proven solid malignancy that is metastatic or
unresectable with metastatic peritoneal carcinomatosis; as this entity may be
difficult to image, peritoneal disease can be documented through other modalities
such as operative notes, clinical notes/symptoms, etc as well as imaging

- Patients must be refractory to standard therapy or have no acceptable standard
treatment options

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1

- Life expectancy of greater than 3 months

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin =< 1.5 X upper limit of normal (ULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
=< 2.5 X ULN

- Creatinine =< 1.5 X ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients
with creatinine levels above institutional normal

- Magnesium >= lower limit of normal (LLN)

- Calcium within normal limit (WNL)

- No surgery, hormonal therapy or chemotherapy within four weeks

- No previous abdominal radiation; if the patient has received previous pelvic
radiation there should not be any overlap between the current and previous radiation
fields

- Toxicities of prior chemotherapy recovered to grade 1 or less except for stable grade
2 peripheral neuropathy

- Negative pregnancy test if premenopausal; women of child-bearing potential and men
must agree to use adequate contraception (hormonal or barrier method of birth
control; abstinence) prior to study entry and for the duration of study
participation; should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

- Archival tumor sample collection with a tumor block is required for all enrolled
patients when available; if no block can be released per institutional policy, 10 to
20 unstained slides may be substituted; slides should have a positive charge and a
thickness of 3 to 5 microns; if the only tissue sample available is a fine needle
aspirate (FNA), the patient will still be considered eligible

- Patients with central nervous system (CNS) metastases to be stable after therapy for
> 3 months and off steroid treatment prior to study enrollment

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients who are currently receiving any other investigational agents

- Brain metastases: patients with treated and stable brain metastasis for 3 months, off
steroids will be eligible

- Patients who demonstrate any clinical evidence of bleeding

- Patients who have demonstrated an inability to swallow oral medications

- Patients who have had a documented malignant bowel obstruction (unless patient had
obstruction as their presenting symptom)

- Patients who have a known hypersensitivity to the components of the study drug, its
analogs or drugs of a similar chemical or biologic composition

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with veliparib; potential risks may also apply to other agents
used in this study

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible

- Patients who have uncontrolled ascites

- Patients with active seizures or a history of seizure are not eligible

- Patients previously treated with poly (ADP-ribose) polymerase 1 (PARP) inhibitors